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Abstract
It has been hypothesised that   co-infectionBackground: Schistosoma
exacerbates HIV progression, and hence anthelminthic intervention in
co-infected individuals will delay it. We evaluated effects of high-intensity
versus low-intensity praziquantel treatment of schistosomiasis on HIV disease
progression among co-infected patients from fishing populations around Lake
Victoria, Uganda.
: Between August 2012 and September 2015, we conducted anMethods
open-label randomised, controlled trial. Adults, antiretroviral therapy-naïve,
CD4 counts ≥350 cells/μl, HIV and  co-infected, were randomisedS. mansoni 
1:1 to praziquantel (40mg/kg) given quarterly (starting at enrolment) or annually
(starting 12 weeks after enrolment; such that low-intensity participants were still
untreated when sampled at 12 weeks). A non-randomised HIV-positive S.
negative comparison group was recruited. The primary outcome wasmansoni-
mean change in plasma viral load at 12 and 60 weeks.
 In total 363 participants (high-intensity 113, low-intensity 113,Results:
comparison group 137) were recruited; 96 (85.0%), 97 (85.8%) and 107
(78.1%) completed 60 weeks of follow up, respectively. Adjusting for baseline
age and viral load, the geometric mean ratio (aGMR [95%CI]) viral load for
high-intensity vs low-intensity groups at 12 weeks was 0.90 [0.65, 1.25] p=0.55
and at 60 weeks 1.88 [0.78, 4.53] p=0.16. Results in the comparison group
were similar to trial arms. High-intensity, compared to low-intensity, treatment
resulted in substantially lower  prevalence at all follow up visits S. mansoni
(p<0.05).
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 (p<0.05).
 In communities with a high burden of both  and HIVConclusions: S. mansoni 
infection, high-intensity treatment of  does not delay HIVS. mansoni 
progression despite relevant benefit for parasite clearance.
 (17/11/2016)Trial registration: ISRCTN15371662
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Introduction
HIV and helminth co-infections are common in resource 
constrained settings. Globally, an estimated 25% of HIV-positive 
individuals are reported to be co-infected1–4. In Africa this fig-
ure is estimated at 50%5. Some studies have suggested that 
helminth co-infection could lead to faster HIV progression6–9. If 
this is true, interventions that treat helminths could help to avert 
HIV disease progression among co-infected people.
An observational study conducted in Ethiopia among HIV-
positive individuals co-infected with Ascaris or Trichuris 
showed a decrease in HIV plasma viral load after treatment of 
helminths with albendazole;10 however, a systematic review 
that included a randomised trial and four observational studies 
found that evidence regarding the benefit of anti-helminth ther-
apy for HIV viral load, CD4 count, and clinical progression was 
inconclusive11. Subsequently, in Entebbe, Uganda, we found 
that treating pregnant women with albendazole resulted in a 
modest decrease in HIV load12. To date, available studies have 
been limited in design by small sample sizes, short duration 
of follow-up and lack of attention to the possibility of 
species-specific effects.
Effects of Schistosoma mansoni deserve special attention: this 
is a systemic infection with strong immunomodulatory effects. 
These regulatory effects are required for the long-term survival 
of adult worms within the host13, but inflammation against 
egg antigens is also required in order for eggs to migrate from 
mesenteric blood vessels, through the tissues and into the 
intestinal lumen14. Interactions between helminths and HIV, 
mediated by immunological mechanisms, may therefore be 
especially important for schistosomiasis. In addition, HIV- 
Schistosoma co-infection is particularly common among fishing 
communities, such as those on the shores and islands of 
Lake Victoria, where S. mansoni infection is almost universal15 
and HIV prevalence among adults is up to 37%16. These are 
recognised key populations with respect to HIV infection and 
regarded as likely reservoirs for the continuing HIV epidemic 
in the general population. Therefore, any impact of S. mansoni 
co-infection on HIV replication could have far-reaching 
consequences. 
A prospective study in Kenya with a variable duration of 
follow up found no benefit of treatment of S. mansoni on HIV 
load17. In Uganda, we observed a transient increase in viral load 
following treatment with praziquantel18. However, neither we, 
nor our colleagues in Kenya, included an untreated control 
group in these initial studies and thus the impact of praziquantel 
treatment on HIV progression remained unknown. Kallestrup 
and colleagues, in Zimbabwe, included a comparison group and 
found that, at three months, individuals treated for schistosomia-
sis (predominantly S. haematobium) had a smaller increase in 
viral load than individuals who had not been treated19,20.
Given these inconsistent results, we sought to evaluate the effect 
of high-intensity (quarterly) treatment in comparison with 
low-intensity (annual) praziquantel treatment on HIV disease 
progression, in a large, well-powered study, among patients 
co-infected with HIV and S. mansoni from fishing populations 
around Lake Victoria, Uganda. This was aimed at assessing 
possible benefits of more frequent anthelminthic treatment 
among hard-to-reach populations whose access to anti-retroviral 
treatment is limited.
Methods
Trial registration
This trial was registered with the International Standard Regis-
tered Clinical/Social Study Number (ISRCTN) registry on the 
17/11/2016. Trial number: ISRCTN15371662. A completed 
CONSORT checklist is available as Supplementary File 1
Study design. This was an open label randomised controlled 
trial. HIV-positive adults were recruited. Schistosoma mansoni 
infected study participants were randomised to high-intensity 
versus low-intensity praziquantel treatment in the ratio of 1:1. 
The high-intensity treatment group received immediate treat-
ment with two doses of praziquantel (40mg/kg) one week apart 
followed by praziquantel at 12 weeks, and then every 12 weeks. 
The low-intensity treatment group received a single dose of 
praziquantel (40mg/kg) annually (in keeping with standard 
Uganda government policy) the first treatment being delayed 
to 12 weeks from enrolment in order to determine the short-
term effects of treatment by comparison with an untreated group 
and to replicate the Zimbabwe study20. In parallel, we recruited 
a comparison group of HIV-positive individuals with no detect-
able S. mansoni infection. Initially it was planned that the 
comparison group would not receive any praziquantel treat-
ment; later the protocol was amended such that participants 
in this group received praziquantel at 12 weeks to conform 
with standard of care in fishing communities. All participants 
received albendazole 400mg at weeks 12, 36 and 60 in keeping 
with policy for the control of nematode infections. Participants 
were followed for 60 weeks. All treatments were directly 
observed. 
Outcomes. The primary study outcome was log10 plasma HIV-1 
RNA level at 12 and 60 weeks of follow up. Secondary out-
comes were CD4 counts, clinical progression of HIV (defined by 
clinical events such as opportunistic infections, and WHO 
staging) and mortality; and reduction of S. mansoni infection 
prevalence and intensity. Immunological investigations in this 
cohort will be reported separately.
Study setting. The study was conducted in fishing communi-
ties on the shores of Lake Victoria in Masaka district, Uganda, 
where HIV prevalence among adults was estimated to be 29% and 
S. mansoni infection more than 50%16,21,22.
Inclusion and exclusion criteria. Inclusion criteria were age 
at least 18 years, HIV and S. mansoni co-infection, antiretro-
viral therapy (ART) naïve, not in advanced HIV WHO stage III 
or Stage IV, CD4 T cell count >350cells/mm3 (i.e. not eligible 
for ART initiation according to prevailing guidelines at the time 
of the study); willing and consenting to provide laboratory 
specimens for stool tests, HIV viral loads, CD4 count, full 
blood count; available for follow up for 15 months and willing 
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to provide locator information for tracking purposes. Partici-
pants were excluded from the study if they met any one of the 
following criteria: women pregnant or planning to be preg-
nant; had taken praziquantel in the preceding three months; had 
symptomatic helminth infection (Hb <8g/dl, bloody diarrhoea, 
clinically apparent liver disease (vomiting blood, hepatosplenom-
egaly)); had high-intensity of S. mansoni infection (egg count 
>2000 eggs/g; these received immediate praziquantel treat-
ment). Enrolment to the comparison group followed similar 
criteria except that participants had to be S. mansoni negative 
on analysis of three stool samples by microscopy. 
Study procedures and measurements. Screening visits: Trained 
field workers mobilised the targeted population through house 
to house HIV counselling and testing. Those found to be HIV-
infected were referred to the study clinic at Lambu fish landing 
site, which is the largest fishing village in the study area located 
about 50km from Masaka town. After written informed consent, 
they were requested to provide three stool samples on consecu-
tive days to ascertain S. mansoni infection status. During the 
screening visit, blood samples were also taken for CD4 count 
and urine from women for pregnancy testing, to complete the 
eligibility assessment. Volunteers were then encouraged to 
return within 2 weeks for enrolment.
Randomisation (enrolment visit): During this visit, individuals 
who met the study criteria were enrolled and baseline clini-
cal history and examination including WHO HIV staging were 
conducted (Baseline questionnaire available as Supplementary 
File 2). Blood samples were collected for plasma viral load 
levels and CD4 counts. Eligible participants were randomly 
allocated to one of the two treatment groups (high-intensity or 
low-intensity praziquantel treatment) using random permuted 
blocks of variable size by an independent statistician. A ran-
domisation list containing study numbers with the allocated 
treatment codes was provided to the study team and partici-
pants who were eligible were assigned the next available number 
until the required sample size was reached. Participants in 
the high-intensity group received the first praziquantel dose 
(directly observed) during the enrolment visit, while treatment 
was deferred for those in the low-intensity group to the 
12 weeks’ visit. At each visit, treatment was given after blood 
and stool samples had been collected. Neither participants 
nor investigators were masked as to treatment allocation.
Similar processes were followed for the comparison group 
except that these participants were S.mansoni negative on all 
three stool samples.
Follow-up visits: From the enrolment visit, participants were 
scheduled to return every 12 weeks until their exit. Partici-
pants in the high-intensity group made an additional visit one 
week after enrolment to receive their second dose of praziquan-
tel. At every follow-up visit, clinical evaluation, urine pregnancy 
testing (women), praziquantel administration for those in 
the high-intensity group and plasma storage were undertaken. 
CD4/CD8 counts, S. mansoni infection (single stool tests and 
circulating anodic antigen (CAA)) were conducted every 3 months 
starting from enrolment day. Plasma viral load assessments 
were done at enrolment, week 12 and week 60.
Laboratory analysis
Stool analysis: Each stool sample was processed and evalu-
ated using the Kato-Katz technique23. Two slides were made 
from each sample. Slides were examined within 30 minutes 
of preparation for hookworm eggs, and the following day for 
other ova, including S. mansoni. The presence of other helminth 
eggs was recorded and the burden of infection based on the 
number of eggs per gram of stool calculated according to WHO 
criteria24,25.
Blood samples: Serological testing for HIV-1 was performed 
using Alere determine™ rapid test HIV1/2,Cat/ref7D2343 Abbott, 
Japan, with all positive tests confirmed by Statpack (HIV1/2STAT-
PAK DIPSTICK Cat/refHIV303 Inverness, USA) with Unigold 
(Trinity Biotech Uni-Gold HIV Cat/ref120652, Ireland) as 
tie-breaker (the prevailing Uganda Ministry of Health algorithm 
at the time of the study). The CD4 lymphocyte count was deter-
mined using Multiset™ software DR-DOS 5.0 system, V1.4 
on a FACSCalibur machine (Becton Dickinson, USA). Plasma 
HIV-1 RNA was quantified using the Ampliprep/Taqman V2.0 
kit Cat number; 05212294190, Roche Molecular systems Inc, 
Pleasanton, USA HIV-1 viral load assay, which has been shown 
to quantify the subtypes of HIV-1 prevalent in Uganda and 
had a detection level of 20 copies of viral RNA/mL. Serum 
CAA was assessed, after all samples had been collected, to 
define S. mansoni infection status and intensity more precisely: 
Plasma CAA was measured using the up-converting phos-
phor lateral flow assay in three sets; (set 1) >50pg/ml was 
considered positive, 20–50pg/ml indecisive and <20pg/ml nega-
tive, (set 2) >30pg/ml was considered positive, 10–30pg/ml 
indecisive and <10pg/ml negative and (set 3) >30pg/ml was con-
sidered positive, 13–30pg/ml indecisive and <15pg/ml negative21. 
All Laboratory investigations were performed at MRC/UVRI 
and LSHTM Uganda Research Unit clinical diagnostics 
laboratory.
Ethical considerations
The study was approved by Uganda Virus Research Institute 
(UVRI) Research Ethics Committee (REC), GC/127/12/02/01 and 
Uganda National Council for Science and Technology (UNCST), 
HS1141. To address challenges of delayed treatment among 
those randomised to the low-intensity group, in relation to direct, 
helminth-induced pathology, we excluded people who were 
symptomatic, or with a high egg burden (>2000epg), and likely 
to benefit from immediate treatment. When participants became 
eligible for ART (according to the prevailing Uganda Ministry 
of Health guidelines) they were immediately referred to a local 
ART provider.
Role of the funding sources
The research leading to these results was funded primarily 
from the European Community’s Seventh Framework Pro-
gramme (FP7/2007–2013) under EC-GA n° 241642. As well, the 
research was supported by the UK Medical Research Council 
(MRC) and the UK Department for International Development 
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(DFID) under the MRC/DFID Concordat agreement. AME 
was supported by a Wellcome Trust senior fellowship, grant 
number 095778. The funders did not have access to the data and 
were not involved in the analysis or interpretation of the results 
and did not provide input regarding the decision to publish this 
manuscript.
Statistical methods
Sample size estimation was based on evaluation of the primary 
outcome: viral load measured at study exit among participants 
treated with high-intensity, compared to those on low-intensity, 
praziquantel. We aimed to recruit and follow to completion 
188 HIV and S. mansoni co-infected participants, giving 
approximately 89% power to detect as significant a differ-
ence in log10 viral load copies/mL at 60 weeks of 0.35 log10 
copies/mL. These assumptions were based on the baseline viral 
load in the rural community cohort in Uganda (unpublished) 
and a within group standard deviation in the log10 copies/mL of 
0.75. Due to the anticipated loss to follow up of 20% (estimated 
from the 18 months’ fisher folk cohort)26 the overall sample size 
was increased to 226 participants (113 per group).
Data handling and analysis: Data were double-entered and veri-
fied in Microsoft Access 2003 (Microsoft Corporation, Redmond, 
WA) and analysed using Stata 14 (Stata Corp, College Station, 
Texas, USA). Participant baseline socio-demographics and 
clinical characteristics were summarised using counts and per-
centages, by study group, for categorical variables and means and 
standard deviation (SD) for continuous variables. The analysis 
was by intention to treat (ITT). The prevalence of S. mansoni and 
other helminth infections, and egg counts (transformed on 
natural logarithm), were compared between the study groups 
using Chi-square tests and geometric means respectively. The 
viral loads showed skewed distributions, with a number of 
results (61-overall (12 at baseline)) as undetectable. An offset 
from zero of 10 copies/mL was added to all the viral loads, 
to allow suitable logarithmic analysis. Results were trans-
formed to log10 (viral loads) and analysed by linear regression 
using bootstrapping with 10,000 iterations. Regression coeffi-
cients and confidence limits were back-transformed to express 
results as ratios of geometric means. All the primary analyses 
were adjusted for baseline age and viral loads and included all 
participants to the end of follow up, regardless of whether or 
not they initiated antiretroviral treatment. Similar approaches 
were followed for CD4 counts though the transformation was 
on natural logarithm and no corrections were made. A Kaplan 
Meier curve with log-rank test was used to compare the 
clinical course of HIV disease (WHO staging) between the study 
groups. Mortality between the groups was compared by 
proportions.
Two sensitivity analyses were performed: one, for the trial 
analysis, excluding viral loads and CD4 count results of the 
participants that initiated ART during the trial and those with 
baseline undetectable viral loads; the other for analyses of the 
comparison group, excluding individuals found to have S. mansoni 
infection at any time point. The exclusion in the latter first 
considered all with indecisive CAA results (10–30pg) as negative 
and secondly as positive. Similar approaches as above were 
followed.
Results
Study profile: Between August 2012 and September 2015, a total 
of 854 participants were screened and 363 (42.7 %) enrolled 
(113 in each of the high-intensity and low-intensity groups 
and 137 in the comparison group). The most common reason 
for exclusion was CD4 count <350 cells (Figure 1). We also 
excluded two participants, one in each trial group, that were 
randomised in error. A total of 36 participants were lost during the 
trial; loss was similar between the trial groups. Fifty-three (15 
high-intensity, 16 low-intensity and 22 comparison group) 
participants initiated antiretroviral treatment during follow up, 
on average 3 participants per visit.
Participant characteristics at baseline: Participants’ baseline 
characteristics are presented in Table 1. The characteristics were 
similar in the two trial groups except that participants in the high-
intensity group were slightly younger, a smaller proportion was 
single (never married), and the prevalence of other helminths 
(Hookworm, Ascaris, and Trichuris) was lower than in the 
low-intensity group. The comparison group had a higher propor-
tion of women compared to the trial groups, reflecting the lower 
prevalence of S. mansoni infection among women than men in 
these communities. The baseline CD4 count and viral loads were 
comparable in all the study groups.
A total of 300 (82.6%,) participants completed the study follow 
up at 60 weeks and had the primary outcome determined. Study 
completion did not differ by the trial arm, standard 97 (85.8%), 
intensive 96 (85.0%) and comparison 107 (78.1%) p=0.202. 
A higher proportion of females (24.6%) did not complete the 
study follow up compared to 14.1% of the males p=0.014, 
but otherwise completers and non-completers were similar 
in regards to other baseline characteristics.
HIV viral load: The primary objective was to compare the effect 
of high-intensity versus low-intensity treatment with prazi-
quantel on HIV disease progression by comparing viral loads 
between baseline and 12 weeks, and between baseline and 60 
weeks in the two study groups. There was no statistical evidence 
of difference in mean log10 viral loads between the high-intensity 
and low-intensity groups at 12 weeks, p=0.55 (Table 2). After 
adjusting for baseline age group and viral load, the geometric 
mean ratio (aGMR) for high-intensity vs low-intensity treat-
ment was 0.90; 95%CI (0.65, 1.25), p=0.55. There was a slightly 
higher mean log10 viral load in the high-intensity group com-
pared to low-intensity group at 60 weeks: after adjusting for 
baseline age group and viral load, the aGMR was 1.88; 95%CI 
(0.78, 4.53), p=0.16. Excluding those with undetectable viral 
load at baseline, and those that initiated ART during follow 
up, there was no evidence of a difference in viral load at 60 
weeks between the high-intensity and low-intensity treatment 
groups (aGMR 1.01 95%CI (0.64, 1.95), p=0.71).
The comparison group had patterns of viral load change similar to 
the low-intensity group.
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Figure 1. CONSORT flow diagram. PZQ - praziquantel.
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Table 1. Baseline information by randomisation group and non-randomised comparison group.
Number (%)
Characteristic Category
High-intensity PZQ 
(n=113)
Low-intensity PZQ 
(n=113)
Comparison 
(n=137)
Sex
Male 87(77.0) 90(79.7) 72(52.6)
Female 26(23.0) 23(20.3) 65(47.4)
Age (years) Median (IQR) 29 (24-33) 30 (26-36) 30 (26-36)
Age group
18–24 29(25.7) 21(18.6) 25(18.3)
25–34 64(56.6) 55(48.7) 62(45.2)
35–59 20(17.7) 37(32.7) 50(36.5)
Education
None 11(9.7) 10(8.9) 12(8.8)
Primary 88(77.9) 86(76.1) 102(75.4)
Secondary 14(12.4) 17(15.0) 23(16.8)
Marital
Single, never married 11(9.7) 20(17.7) 14(10.2)
Married 62(54.9) 60(53.1) 82(59.8)
Single, ever married 40(35.4) 33(29.2) 41(30.0)
Occupation
Fishing/related 88(77.9) 83(73.4) 83(73.4)
Small scale business 9(8.0) 8(7.1) 8(7.1)
Bar/restaurant 4(3.5) 7(6.2) 7(6.2)
Other 12 (10.6) 15(13.3) 15(13.3)
CD4 count Mean ln (SD) 6.5(0.33) 6.4(0.31) 6.4(0.36)
†Viral Load Mean log10 (SD) 4.5(1.01) 4.5(0.74) 4.4(0.98)
Schistosoma (Kato 
Katz microscopy)
Prevalence 113(100) 113(100) 0(0.0)
*Geometric mean 
egg count (95%CI) 244.2(192.3-310.1) 228.0(181.6-286.3) N/A
Schistosoma (serum 
circulating anodic 
antigen (CAA))
Prevalence 99(87.6) 101(89.4) 47(34.3)
*Geometric mean 
concentration pg/ml 
(95%CI)
1708.2(1178.6-
2475.6)
1877.8(1277.3-
2760.7)
482.2(293.3-
792.7)
Other worms Prevalence 11(9.7) 21(18.6) 22(16.1)
PZQ praziquantel. †12 volunteers (9-Low-intensity PZQ arm and 3-comparison) had undetectable viral loads at baseline. 
* Geometric mean among those infected. Figures in brackets are percentages unless otherwise indicated in column 2, 
IQR-Interquartile range.
Table 2. Adjusted ratio of geometric means for the primary outcome (viral load) and CD4 counts at 12 and 60 
weeks by randomisation and comparison group.
Outcome Randomisation Group 12 weeks 60 weeks
Mean (SD) aGMR* P-value Mean (SD) aGMR* P-value
Viral load Low-intensity PZQ 4.2 (1.16) 1.00 3.6 (1.57) 1.00
High-intensity PZQ 4.3 (1.08) 0.90 (0.65-1.25) 0.55 4.0 (1.22) 1.88 (0.78-4.53) 0.16
Comparison 4.1 (1.22) 1.18 (0.83-1.69) 0.36 3.6 (1.47) 0.92 (0.39-2.18) 0.84
CD4 count Low-intensity PZQ 6.3 (0.38) 1.00 6.3 (0.40) 1.00
High-intensity PZQ 6.4 (0.38) 0.99 (0.93-1.07) 0.96 6.3 (0.40) 0.94 (0.86-1.02) 0.15
Comparison 6.3 (0.41) 0.99 (0.93-1.07) 0.97 6.2 (0.42) 1.00(0.91-1.09 0.98
PZQ praziquantel. *aGMR - adjusted ratio of geometric means, adjusted for age and baseline viral load or CD4 count; “Low-intensity 
PZQ” was the reference group
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Table 3. Schistosoma prevalence and geometric mean egg count by study week and randomisation and comparison groups.
Time point Prevalence geometric mean)
High-intensity 
PZQ (n=113)
Low-intensity PZQ 
(n=113) p-value^ Comparison n=137 p-value$
12 weeks 
Kato Katz microscopy
Prevalence 23/105 (21.9%) 79/109 (72.5%) <0.01 9/124 (7.3%) <0.01
*Geometric mean egg 
count (95%CI) 
115.7 (73.9-181.1) 288.4 (215.8-385.6) <0.01 82.3 (32.8-206.4) 0.43
CAA
prevalence 66/97 (68.0%) 86/97 (88.7%) <0.01 13/82 (15.9%) <0.01
*Geometric mean pg 
CAA / mL (95% CI)
369.1 (247.2-551.2) 2041.5 (1395.5-2986.7) <0.01 219.5 (100.6-478.8) 0.44
36 weeks
Kato Katz microscopy
Prevalence 9/98 (9.2%) 22/99 (22.2%) 0.01 11/119 (9.2%) 0.99
*Geometric mean egg 
count (95%CI)
61.3 (33.1-113.6) 136.1 (90.2-205.3) 0.05 38.7 (27.6-54.3) 0.17
60 weeks
Kato Katz microscopy
Prevalence 6/91 (6.6%) 31/96 (32.3%) <0.01 8/107 (7.5%) 0.81
*Geometric mean egg 
count (95%CI) 
54.6 (22.4-133.0) 191.5 (124.5-294.7) 0.01 59.1 (36.4-95.9) 0.55
CAA
prevalence 26/89 (29.2%) 69/94 (73.4%) <0.01 14/103 (13.6%) 0.01
*Geometric mean pg 
CAA / mL (95%CI)
295.5 (152.0-
574.4)
695.1 (463.8-1041.6) 0.03 103.3 (62.8-169.9) 0.04
Other helminths 
12 weeks Prevalence 6/106 (5.7%) 13/109 (11.9%) 0.11 9/124 (7.3%) 0.63
36 weeks Prevalence 7/98 (7.1%) 7/99 (7.1%) 1.00 5/119 (4.2%) 0.37
60 weeks Prevalence 1/91 (1%) 1/96 (1%) 0.99 0/109 (0.0%) 0.60
PZQ praziquantel. * Geometric mean among those infected, ^High-intensity PZQ to Low-intensity PZQ group, $ High-intensity PZQ vs comparison, CAA-
serum circulating anodic antigen
CD4 count: There were no significant differences in mean 
CD4 count between the study groups at any time during 
follow up, even after adjusting for baseline age group and 
CD4 count; high-intensity vs low-intensity at 60 weeks aGMR 
0.94 (0.86, 1.02), p=0.15 (Table 2). The comparison group did 
not differ from either trial group.
Schistosoma mansoni and other helminth infections: The preva-
lence of S. mansoni as assessed by microscopy was substan-
tially lower in the high-intensity treatment group compared to 
the low-intensity group at 12 weeks (21.9% vs 72.5% (p<0.01); 
as expected, given that the low-intensity group was still untreated 
at this time) and at 60 weeks (6.6% vs 32.3% (p<0.01). Cor-
responding reductions in geometric mean egg counts among 
those infected were observed (Table 3). Although the prevalence 
of other helminths was somewhat higher in the high-intensity 
group at baseline, it did not differ significantly between the 
two study groups during follow up (Table 3). The prevalence of 
S. mansoni as assessed by CAA was also substantially lower 
in the high-intensity treatment group compared to the low-
intensity at 12 weeks and 60 weeks: 74.2% vs 94.9% (p<0.01) 
and 29.2% vs 73.4% (p<0.01) respectively.
Although the comparison group had no evidence of S. mansoni 
infection by microscopy at baseline, infection was detected 
by CAA in 41.5%; in line with this result, a small propor-
tion of comparison group participants were positive by micro-
scopy and by CAA during follow up (CAA-positive 23.2% 
and 13.6% at 12 and 60 weeks, respectively; Table 3). When 
members of the comparison group with S. mansoni infection 
detectable by either method were excluded from the analysis 
of viral load, viral load measurements in this group were still 
similar to the low-intensity group: aGMR 0.94 (0.77–1.15), 
p=0.55 and 0.90 (0.54–1.49), p=0.68 at 12 and 60 weeks (all inde-
cisive CAA results considered as negative). Similar results were 
obtained when indecisive CAA results were considered as positive 
(date not shown).
Mortality and progression to AIDS: In total six participants 
(4-high-intensity and 2-low-intensity group) died during follow 
up. Twenty-five participants (10-high intensity, 5- low intensity 
and 10-comparison arm) progressed in WHO clinical staging 
during follow up. Based on WHO clinical staging, progression 
to AIDS was more likely to occur in high-intensity treatment 
and comparison groups compared to the low-intensity group, 
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although this finding was not statistically significant (log-
rank chi-square (low-intensity vs high-intensity) 2.08, p=0.15; 
and log-rank chi-square (low-intensity vs comparison group) 
0.51, p=0.47 (Figure 2)). 
Discussion
This randomised clinical trial was designed to establish whether 
high-intensity treatment of S. mansoni with praziquantel delays 
HIV disease progression. We used HIV viral load, CD4 count 
and clinical parameters as markers of disease progression. We 
found no benefit of praziquantel treatment of S. mansoni for 
HIV disease progression. If anything, at week 60 of follow 
up, HIV viral loads were slightly higher among participants who 
received high-intensity treatment than among those who received 
low-intensity treatment. In addition, analysis of outcomes in 
the comparison group indicated that S.mansoni infection per se, 
under either treatment regimen, had no effect on HIV disease 
progression.
Our study was not blinded, but it is unlikely that the low-intensity 
group received praziquantel outside the trial protocol since it 
is not widely available in the community clinics and pharma-
cies; the infection prevalence (based on microscopy) and CAA 
concentration at 12 weeks (i.e. prior to the first treatment in 
this group) remained high in this group. A marked difference in 
S. mansoni prevalence, as assessed by Kato Katz microscopy, 
emerged between the low-intensity and high-intensity treatment 
groups by 12 weeks, and persisted during follow up. The more 
sensitive CAA analysis showed that complete clearance of 
infection was slower than it appeared using microscopy of sin-
gle stool samples, and this could have obscured a true effect of 
eliminating S. mansoni during the early part of follow up; how-
ever, a substantial difference had been achieved by 60 weeks. 
Follow up Kato Katz and CAA analyses in the comparison group 
indicated that some members were, in fact, S. mansoni infected 
but a sensitivity analysis restricting the comparison group to 
individuals negative on all tests still showed no evidence of 
statistical difference relative to the trial low-intensity group.
In this study, there was a hint of an adverse effect of treating 
schistosomiasis on HIV load – the aGMR indicated a higher 
viral load in the high-intensity treatment arm, although the 
confidence interval was wide (aGMR 1.88 (95%CI 0.78–4.53). 
This is in agreement with earlier observations in Kisumu, Kenya27 
and in Uganda18,28. The cohort study in Kisumu demonstrated a 
moderate rise in mean HIV-1 plasma viral load among patients 
who received praziquantel treatment, but the study lacked a 
comparison group. Similarly, we previously demonstrated a 
transient rise in plasma HIV viral load in a cohort of HIV- 
S. mansoni co-infected patients in Uganda, more marked among 
subjects with higher intensity S. mansoni infections18. These 
prior studies were limited by short follow up periods and lack 
of treatment randomisation. In terms of mechanism, the factors 
producing the type 2 bias of responses to worm antigens 
released following praziquantel treatment18 may affect the extra-
cellular environment and antigen presenting cells (APC)s that 
determine the functional fate of naïve T cells recognizing HIV 
antigens, priming a phenotype less effective in hindering HIV 
replication. Additionally, the activated, proliferating S. mansoni 
specific CD4 T cells responding to the circulating antigen 
surge might themselves constitute additional targets for HIV 
infection and replication, supporting a transient increase in viral 
load. 
Our findings contrast with the results of the earlier Zimbabwe 
study, the only similar randomised trial of praziquantel treat-
ment to address HIV-related outcomes, which we sought to 
confirm. The Zimbabwe trial was a smaller study, with shorter 
follow up and lower power than this study. The Zimbabwe trial 
included participants with both S. haematobium and S. mansoni; 
infection intensity (at least for S. mansoni) was markedly lower 
than in our study (with mean egg counts of 3–4 epg of stool, 
Figure 2. Volunteers moving up in WHO staging by study group. PZQ – praziquantel.
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compared to our geometric mean of >200 epg)19. Differences 
in infection intensity as well the involved species may explain 
differences in impact on the immune system (and hence on 
HIV replication). Low-intensity infections are more likely 
to be readily cleared by a single dose of treatment.
Our study strengths included a prolonged follow up period, 
sufficient sample size and randomisation of treatment. The 
results provide strong evidence that, in communities with a high 
burden of both S. mansoni and HIV infection, high-intensity 
treatment of S. mansoni does not delay HIV progression despite 
benefits for parasite clearance. Our study limitation included 
a challenge that fishing communities are predominantly males 
and they constituted about 75% of the study population in 
the two randomized groups. However, a subgroup analysis 
stratifying by gender, though underpowered still showed that 
high-intensity treatment of S. mansoni does not delay HIV 
progression in males as well as females. We therefore con-
clude that, unfortunately, treatment of S. mansoni is not likely 
to contribute to mitigating the HIV epidemic among fishing 
communities.
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HIV infection. The authors give PZ to S mansoni infected people, and those on the low intensity
schedule were untreated at 12 weeks so a direct comparison of no treatment with PZ 40 dose was
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schedule were untreated at 12 weeks so a direct comparison of no treatment with PZ 40 dose was
possible in terms of mean change in geometric mean of viral load. The treatment reduced S
mansoni but did not show any impact on mean viral load change.
This is an important study and is highly relevant in a research question where there seem to be
strong beliefs there is an effect, yet effects to date have been mixed but always quite small, and as
such the evidence base is at risk of selective publication and selective reporting. The authors have
therefore done a service to science in ensuring this study, which does not demonstrate an effect,
has been published. They also appear to have adhered to the protocol and not sought secondary
outcomes or subgroup analyses that risk generating spurious results.
It is a fascinating also because the authors were able to evaluate the effect of PZ and treating the
infection in people with HIV that was not suppressed by ARVs. This was because it was conducted
prior to the WHO recommendation to treat all people living with HIV with ARVs irrespective of CD
counts. So this study is “as good as it will ever get” in testing whether treatment has any influence
on HIV progression.
The study is well-written. The background explains studies to date and the gap in the literature
leading to this study. Whilst this is a basic expectation of the background section, so many authors
do not do this or do it badly, surprisingly; I will use this as an example of good practice in our
teaching!  and the methods are clearly explained. The follow up is good and the results well
presented.
It is appropriately reported without any attempt to overinterpret the results. Given the complexity of
the study the authors have good numbers recruited. Very few people were started on ARVs during
the course of the study and the sensitivity analysis showed this did not, by chance, influence the
results, which might have happened if there was chance imbalance in the numbers treated in
comparator groups.
The one point that would really help understand the context-and this is a broader concern with
these studies of this kind around treating helminths in HIV (including the studies of albendazole
used for soil transmitted helminth infection in people with HIV) is the ambiguity around the purpose
of the study: is it truly believed by the authors that this could be potentially important component of
treatment by delaying progression of the disease as stated in the first sentence of the discussion?
Or that treatment of schisto could have some public health impact on transmission as outlined at
the end of paragraph 3 in the introduction? Or is it simply a randomised explanatory trial to
elucidate immune mechanisms with helminth infection? This is the only strongly recommended
change I would want to see in the amended version.
With the absence of any demonstrable effect in this study, it seems most unlikely, given the
dramatic effectiveness of ARVs in viral suppression, that further studies would be worthwhile.
Indeed, given patients would need to be on ARVS, with such small putative possible effects of the
treatment, the studies would have to be extremely large, probably so large that no-one would fund
them. I think it would be extremely worthwhile reporting in their discussion. 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
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I have read this submission. I believe that I have an appropriate level of expertise to confirm that
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 26 July 2018Referee Report
https://doi.org/10.21956/wellcomeopenres.15987.r33493
   Judd L. Walson
Departments of Global Health, Medicine (Infectious Disease), Pediatrics and Epidemiology, University of
Washington, Seattle, WA, USA
This is an interesting manuscript presenting the results of a randomized trial comparing high-intensity
treatment (frequent quarterly treatment) vs low intensity (annual) of schistosomiasis in HIV co-infected
individuals. This paper adds to a previous RCT demonstrating lack of benefit with the use of empiric
quarterly praziquantel in HIV infected individuals . Overall, this was an ambitious attempt to conduct a
rigorous trial given considerable challenges in the selection of appropriate patients, potential for
alternative treatments (such as ART) to impact the outcomes and need for high retention.
Unfortunately, there are a number of critical issues with the design and conduct of the trial that make the
interpretation of these data difficult.
Overall, one cannot expect to see differences in HIV VL above and beyond reductions that would
be expected with initiation of ART in antiretroviral naïve individuals. As such, the actual population
for whom any expected benefit would need to exclude these individuals (which was done in a
secondary analysis). Including these individuals in the primary analysis is problematic as they are
not going to benefit from the intervention and they only serve to dilute the impact amongst the
population who may benefit. Per my calculations, removing these individuals would leave 81
individuals per arm who were treated and did NOT receive ART. This suggests that the actual
study was dramatically underpowered to detect the effect size for which it was designed. This is a
significant limitation of the study. In addition, the fact that 12 individuals had undetectable VL at
baseline is concerning, suggesting either that there were individuals who were included that had
already initiated ART or that there were some fundamental issues with the laboratory in detecting
VL. While it would be expected that some individuals in a population could be long-term
non-progressors and have low to undetectable VL in the absence of treatment, the number
observed here is quite high and raises some concerns.
 
The inclusion of a group of HIV infected, schisto negative “controls” does not add to the study.
1
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The inclusion of a group of HIV infected, schisto negative “controls” does not add to the study.
These individuals are likely to be different in many unmeasured ways from the coinfected
population and any comparison of this group is likely subject to considerable confounding. I found
that the inclusion of this group detracted from the quality of the overall study.
 
The very high rates of LTFU in this study are concerning. Other RCTs with a similar length of follow
up in East Africa among HIV infected adults achieve retention rates of greater than 90-95%. The
high rates of LTFU suggest that there may have been differential loss and have introduced
significant bias.
 
Important to note that the intervention also included albendazole – any observed effect could also
have been attributed to this.
 
The exclusion of individuals with high intensity infection, while perhaps ethically necessary, is
problematic for the interpretation of these data. It is likely that these are the individuals most likely
to benefit from the intervention and the exclusion of this group makes it difficult to draw any
conclusions from these results.
 
Please explain how allocation concealment was maintained. It appears that study staff were
provided the randomization lists and allowed to sequentially assign groups. This is subject to bias
and may not have resulted in true random allocation. If this was indeed the case, please restate
that this was a pseudorandomized trial.
 
Please explain what the authors mean when they say that in each group one participant was
“randomized in error”.
 
In table 2, please clarify the CD4 count values presented.
 
The authors suggest that there was previously only one RCT in Zimbabwe evaluating HIV
outcomes. This is not the case (as noted above). Please review the literature to ensure that all
relevant prior trials are summarized and included in the discussion.
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